Get the Stockscreener App
11.00
4.27%
0.45
After Hours:
10.68
-0.32
-2.91%
Jyong Biotech Ltd stock is traded at $11.00, with a volume of 45,623.
It is up +4.27% in the last 24 hours and up +0.00% over the past month.
Jyong Biotech Ltd is a science-driven biotechnology company based in Taiwan and is committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia (primarily Taiwan and mainland China). It has been dedicated to the research and development of new drugs with high safety and efficacy. It has been developing a series of drug candidates, including one core drug candidate at NDA stage, one clinical-stage key drug candidate and other preclinical-stage drug candidates.
See More
Previous Close:
$10.55
Open:
$11.07
24h Volume:
45,623
Relative Volume:
13.91
Market Cap:
$836.30M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+0.00%
1M Performance:
+0.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$10.58
$11.57
1-Week Range:
$10.50
$12.30
52-Week Range:
$10.50
$12.30
Jyong Biotech Ltd Stock (MENS) Company Profile
Compare MENS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MENS
Jyong Biotech Ltd
|
11.00 | 882.68M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Jyong Biotech Ltd Stock (MENS) Latest News
Jyong Biotech Ltd.’s Quiet Period Set To Expire on July 28th (NASDAQ:MENS) - Defense World
Jyong Biotech shares rise 3.85% in premarket after rating upgrade and CEO's Nasdaq bell ringing. - AInvest
Yong Biotech Ltd (Nasdaq:MENS) Marks Milestone at Nasdaq Composite MarketSite - Kalkine Media
Jyong Biotech Ltd. Rings the Closing Bell - Nasdaq
Jyong Biotech shares fall 10.24% in premarket after recent gains following Nasdaq listing. - AInvest
Jyong Biotech shares fall 4.92% in after-hours following a 34.80% surge post-Nasdaq listing and 11.04% gain over the past five days. - AInvest
Jyong Biotech shares rise 2.11% intraday as biotech sector gains and company completes $20M IPO. - AInvest
Jyong Biotech shares rise 11.82% intraday after successful $20 million IPO and addition to Nasdaq Composite Index. - AInvest
Jyong’s $20M US IPO to help refile NDA of urological botanic drug - BioWorld MedTech
Jyong Biotech Soars 11.13% Post $20M IPO - AInvest
MENSJyong Biotech Ltd. Latest Stock News & Market Updates - Stock Titan
Aurora Cannabis, Bitdeer Technologies Group And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Jyong Biotech Ltd. IPO opens at $15 after pricing at $7.50 per share - Investing.com Nigeria
Jyong Biotech Ltd. Announces Pricing of $20 Million Initial Public Offering - GlobeNewswire
Jyong Biotech Seeks US IPO On Thin Capitalization And Uphill Regulatory Battle (MENS) - Seeking Alpha
MENS IPO NewsUrinary disease biotech Jyong Biotech sets terms for $19 million US IPO - renaissancecapital.com
Commercial-ready Taiwanese biotech developing therapies for urinary diseases. - renaissancecapital.com
JYB IPO NewsUrinary disease biotech Jyong Biotech withdraws $40 million US IPO - renaissancecapital.com
Jyong Biotech Ltd. Begins U.S. IPO Rollout (Pending:JYB) - Seeking Alpha
Laxton Investments Company Ltd. v. Jyong Biotech Ltd. et al: Originating Summons - OffshoreAlert
Jyong Biotech Ltd Stock (MENS) Financials Data
There is no financial data for Jyong Biotech Ltd (MENS). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.87%
0.17%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):